An important consequence of controlling JAK/STAT pathways is the attenuation of interferon-γ (IFNγ) and interleukin-2 (IL-2) signaling, which can impair the recognition and elimination of cancer cells by T cells [98,99]. Here, IL2 is linked to cancer.